Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,293 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | recruiting | Phase 2 | 44 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05278715 | Modified CV Regimen in Optic Pathway Glioma | recruiting | Phase 2 | 75 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06595186 |
| JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) |
| recruiting |
| Phase 2 |
| 25 |
| JenKem Technology Co., Ltd.INDUSTRY |
| 1 |
| Sep 19, 2024 |
| clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06327451 | Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma | recruiting | Phase 2 | 50 | Tianjin Medical University General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06297512 | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | recruiting | Phase 2 | 20 | Iacopo SardiOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05525273 | Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma(Swecranio) | recruiting | Phase 2 | 25 | Eva Marie Erfurth, MD, PhDOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06220552 | The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05964569 | Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma(INDIGO) | recruiting | Phase 2 | 120 | University Hospital HeidelbergOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06159478 | Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume) | recruiting | Phase 2 | 32 | National Cancer Center, JapanOTHER_GOV | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma(GLIOSUN) | recruiting | Phase 1 / Phase 2 | 226 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 28 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05512351 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma | recruiting | Phase 2 | 80 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04316039 | Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery | recruiting | Phase 2 / Phase 3 | 250 | West China HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Oct 15, 2024source: clinicaltrials